Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.60 |
| ▸ | AR | P10275 | 6/20 | 0.60 |
| ▸ | SHBG | P04278 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.60 |
| ▸ | PGR | P06401 | 2/20 | 0.60 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | SNCA | P37840 | 2/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.60 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.60 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.60 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.55 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28201393 | 0.89 | CYP19A1 (0.60) | CYP19A1ARSHBGLMNAHSD17B10 | |
| SCHEMBL9436548 | 0.88 | CYP19A1 (0.59) | CYP19A1ARSHBGLMNAHSD17B10 | |
| SCHEMBL3633398 | 0.87 | CYP19A1 (0.52) | CYP19A1ARSHBGLMNAHSD17B10 | |
| SCHEMBL3331322 | 0.86 | ALDH1A1 (0.62) | ARSHBGLMNAHSD17B10NR3C1 | |
| SCHEMBL4419947 | 0.86 | CYP19A1 (0.68) | CYP19A1ARSHBGLMNAHSD17B10 | |
| SCHEMBL4111276 | 0.86 | CYP19A1 (0.68) | CYP19A1ARSHBGLMNAHSD17B10 | |
| SCHEMBL9420189 | 0.86 | CYP19A1 (0.68) | CYP19A1ARSHBGLMNAHSD17B10 | |
| SCHEMBL4111278 | 0.86 | CYP19A1 (0.68) | CYP19A1ARSHBGLMNAHSD17B10 | |
| SCHEMBL13752956 | 0.86 | CYP19A1 (0.68) | CYP19A1ARSHBGLMNAHSD17B10 | |
| SCHEMBL527919 | 0.86 | CYP19A1 (0.68) | CYP19A1ARSHBGLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728013-A | Methods of treating prolonged pregnancy and complications of menstruation or pregnancy | 斯坦福大学托管董事会 | 2022-07-08 | — | — | CN | claimed |
| WO-2009152269-A2 | METHODS OF QUANTIFYING BIOMARKERS | HEALTH RESEARCH, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-7495107-B2 | Method for manufacturing isoxazole derivative or dihydroisoxazole derivative | RIKKYO GAKUIN (JP) | 2009-02-24 | — | — | US | claimed |
| US-20060247288-A1 | Method for manufacturing isoxazole derivative or dihydroisoxazole derivative | GAKUIN, RIKKYO (JP) | 2006-11-02 | — | — | US | claimed |
| EP-4585211-A2 | PULLULAN CAPSULES | Capsugel Belgium NV (BE) | 2025-07-16 | — | — | EP | disclosed |
| EP-3609476-B1 | PULLULAN CAPSULES | CAPSUGEL BELGIUM NV (BE) | 2025-06-04 | — | — | EP | disclosed |
| US-11975107-B2 | Compositions and resulting hard capsules comprising hydrophilic coloring foodstuff concentrates | CAPSUGEL BELGIUM NV (BE) | 2024-05-07 | — | — | US | disclosed |
| US-11878079-B2 | Pullulan capsules | CAPSUGEL BELGIUM NV (BE) | 2024-01-23 | — | — | US | disclosed |
| WO-2023094689-A1 | COMPOSITIONS FOR PREVENTING OR TREATING SKIN AGING | ESTETRA SRL (BE) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094690-A1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | ESTETRA SRL (BE) | 2023-06-01 | — | — | WO | disclosed |
| US-20230131084-A1 | PULLULAN CAPSULES | CAPSUGEL BELGIUM NV (BE) | 2023-04-27 | — | — | US | disclosed |
| US-11576870-B2 | Pullulan capsules | CAPSUGEL BELGIUM NV (BE) | 2023-02-14 | — | — | US | disclosed |
| EP-1196179-A2 | HYALURONIC ACID DERIVATIVES FOR THE PREVENTION AND TREATMENT OF CUTANEOUS SCARS | FIDIA ADVANCED BIOPOLYMERS S.R.L. (IT) | 2002-04-17 | — | — | EP | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| WO-2001000190-A2 | HYALURONIC ACID DERIVATIVES FOR THE PREVENTION AND TREATMENT OF CUTANEOUS SCARS | FIDIA ADVANCED BIOPOLYMERS, S.R.L. (IT) | 2001-01-04 | — | — | WO | disclosed |
| EP-1027057-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | Asivi, LLC (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021562-A1 | TREATMENT OF FEMALE SEXUAL DYSFUNCTION | ASIVI, LLC (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
| EP-0053845-A1 | 17-Beta-ethynylsteroids and process for preparing same | MITSUBISHI KASEI CORPORATION (JP) | 1982-06-16 | — | — | EP | disclosed |
| US-4115563-A | Pharmaceutical steroid formulation | STERLING DRUG INC. (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247288-A1 | Method for manufacturing isoxazole derivative or dihydroisoxazole derivative | CYP3A7, NDUFS7, IDH3A | CYP19A1 329/4885AR 2343/4885SHBG 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.